Fetal fibronectin as predictor of successful induction of mid-trimester abortion.

Acta Obstet Gynecol Scand

Department of Gynecology and Obstetrics, and Pathophysiology of Human Reproduction, University of Naples Federico II, Italy.

Published: April 2005

Background: Fetal fibronectin (FFN) in cervical secretion is one of the most effective markers of pre-term and term delivery. The presence of FFN in cervicovaginal secretions has recently been shown to reflect cervical state and an uncomplicated induction of labor at term. This study was designed to determine whether FFN could be a biochemical marker to predict the response to prostaglandins in early mid-trimester abortion.

Methods: The presence of cervical FFN was evaluated by means of qualitative rapid immunoassay in 270 patients, who required second trimester termination of pregnancy at the Department of Gynecology and Obstetrics, University of Naples 'Federico II'. According to the standard protocol of our unit, women received 1.0 mg of gemeprost intravaginally at 3-hr intervals up to a maximum of five suppositories. The induction-to-abortion interval and the percentage of successful abortions within 24 hr in women in the positive FFN group (n=19) were compared with those in the negative FFN group (n=251).

Results: FFN in the cervical secretions was present in seven women (10.2%) at 16-weeks gestation, in seven women (7.5%) at 17-weeks gestation, and in five women (4.5%) at 18-week gestation. Final termination rates were 13 (68.4%) in the fibronectin-positive group and 177 (70.5%) in the fibronectin-negative group. The median abortion interval was similar (14.7 versus 15.1 hr) in both groups.

Conclusions: A positive cervical fetal fibronectin test does not predict a successful medical termination of pregnancy in second trimester abortion. In this setting, the role of fetal cervical fibronectin in cervical ripening is, therefore, questionable.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.0001-6349.2005.00675.xDOI Listing

Publication Analysis

Top Keywords

fetal fibronectin
12
ffn cervical
8
second trimester
8
termination pregnancy
8
ffn group
8
gestation women
8
ffn
7
cervical
7
women
5
fetal
4

Similar Publications

Article Synopsis
  • Preeclampsia is a condition with serious risks for mothers and babies, and new angiogenic markers are being used to help diagnose it quickly in clinical settings.
  • The study analyzed the effectiveness of various point-of-care tests for predicting preeclampsia, focusing on their sensitivity and specificity based on data from 17 relevant studies.
  • Glycosylated fibronectin testing showed promising results with a sensitivity of 0.80 and specificity of 0.84, indicating it could be a valuable tool for clinical decisions regarding preeclampsia in high-risk patients.
View Article and Find Full Text PDF

Objectives: To evaluate glycosylated fibronectin (GlyFn) as a novel biomarker for preeclampsia and preeclampsia-related complications, and to compare GlyFn to traditional biomarkers, including soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF).

Study Design: Secondary analysis of a prospective cohort study (n = 524) with suspected preeclampsia (control), gestational hypertension (GH), or confirmed preeclampsia/hemolysis, elevated liver enzymes and low platelets syndrome (PE/HELLP).

Main Outcome Measures: GlyFn levels in PE/HELLP versus control and GH.

View Article and Find Full Text PDF
Article Synopsis
  • Breast cancer is the leading cause of cancer-related deaths among women globally, with metastasis being a key factor in these fatalities.
  • The study investigates the role of the TEA domain transcription factor 4 (TEAD4) in promoting tumor cell adhesion and migration through the regulation of the adhesion molecule Fibronectin (FN1), highlighting its potential links to cancer metastasis.
  • Curcumin is shown to reduce the migration and invasion abilities of breast cancer cells by inhibiting TEAD4's interaction with the FN1 promoter, suggesting that targeting the TEAD4-FN1 axis could help mitigate breast cancer metastasis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!